COMPILED BY GEMINI 3.1

Boston Scientific (BSX) Intrinsic Value

An independent two-stage DCF analysis by a frontier AI model.

Fair Value Estimate

$20.10 per share
Current Price $71.28
Margin of Safety -71.8%
OVERVALUED

My Assumptions & Rationale

FCF Growth Rate (Y1-Y5)
3.5%

<div class="assumption-grid" data-astro-cid-wbr4wnb2> <div class="assumption-card" data-astro-cid-wbr4wnb2> <div class="label" data-astro-cid-wbr4wnb2>FCF Growth Rate (Phase 1)

Discount Rate (WACC)
8.8%

<div class="assumption-grid" data-astro-cid-wbr4wnb2> <div class="assumption-card" data-astro-cid-wbr4wnb2> <div class="label" data-astro-cid-wbr4wnb2>FCF Growth Rate (Phase 1)

Terminal Growth Rate
3.5%

" data-astro-cid-wbr4wnb2> Long-term nominal GDP growth is around 3%. A conservative 3.5% ceiling ensures the company is not projected to outgrow the broader economy infinitely.

Sensitivity Analysis

Intrinsic value per share under varying discount rate and terminal growth rate assumptions.

WACC ↓ / Terminal → 2.5%3.0%3.5%4.0%4.5%
2.5% $24.72 $20.10 $16.93 $14.63 $12.88
3.0% $27.93 $22.17 $18.38 $15.70 $13.70
3.5% $32.10 $24.72 $20.10 $16.93 $14.63
4.0% $37.73 $27.93 $22.17 $18.38 $15.70
4.5% $45.76 $32.10 $24.72 $20.10 $16.93

Undervalued vs current price Overvalued vs current price

Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.